ライフサイエンスコーパス: diuretics

1 ct of empagliflozin in combination with loop diuretics.

2 c shock includes inotropes, vasopressors and diuretics.

3 ving dialysis and 847 discharged on thiazide diuretics.

4 thier patients are simply more responsive to diuretics.

5 aemia may lead to the creation of uricosuric diuretics.

6 imilar after the exclusion of individuals on diuretics.

7 es of GS with a blunted response to thiazide diuretics.

8 blockers, angiotensin receptor blockers, and diuretics.

9 l outcomes than those not discharged on loop diuretics.

10 estinal bleeding, and patients that required diuretics.

11 istry, 9,866 (39%) received no pre-admission diuretics.

12 e management, typically addressed using loop diuretics.

13 d overload despite significant doses of loop diuretics.

14 the target of the clinically important loop diuretics.

15 ngiotensin-converting enzyme inhibitors, and diuretics.

16 es of antihypertensive medications, thiazide diuretics.

17 randomized to ultrafiltration or intravenous diuretics.

18 miloride 40 mg was as effective as the other diuretics.

19 randomized to ultrafiltration or intravenous diuretics.

20 oportion of instructions given for fluid and diuretics.

21 of SPIRO and a potential target for thiazide diuretics.

22 cluding vasopressors, intravenous fluids, or diuretics.

23 o in addition to standard therapy, including diuretics.

24 bitors plus diuretics and beta-blockers plus diuretics.

25 diabetes development than beta-blockers and diuretics.

26 risk of CVD mortality vs beta-blockers plus diuretics.

27 es to the cytoprotection afforded by osmotic diuretics.

28 U-50488H and bremazocine are analgesics and diuretics.

29 erting enzyme inhibitors, beta blockers, and diuretics.

30 nce of treatment effect modification by loop diuretics.

31 lance and related this to renal clearance of diuretics.

32 ervative care and was started on digoxin and diuretics.

33 beta-blockers, calcium channel blockers, or diuretics.

34 and the available data on the optimal use of diuretics.

35 was confirmed by the natriuretic response to diuretics.

36 positive effect, such as glaucoma, or act as diuretics.

37 ir actions on glycemic control or as osmotic diuretics.

38 el approach to potentiate the action of loop diuretics.

39 , 0.80-1.08), CCBs (1.27%; 0.96, 0.82-1.11), diuretics (1.30%; 0.98, 0.84-1.13), other controls (1.43

40 , 0.88-1.07), CCBs (2.11%; 1.05, 0.96-1.13), diuretics (2.02%; 1.00, 0.90-1.11), or other controls (1

41 uded; at baseline, 3352 (50.5%) did not have diuretics, 2195 (33.1%) had diuretic doses between 1 and

42 agliflozin group reported intensification of diuretics (297 versus 414 [HR, 0.67; 95% CI, 0.56-0.78;

43 therapy (23.0% vs. 4.9% and 9.2%, p mu .01), diuretics (4.2% vs. 2.6% and 0.8%, p mu .001), or vasopr

44 0%) of beta-blockers, 10 of 11 RCTs (91%) of diuretics, 5 of 7 RCTs (71%) of calcium channel blockers

45 s 43.8%), ivabradine (8.3% versus 3.6%), and diuretics (94.2% versus 78.6%) and less often renin-angi

46 At randomization, patients were receiving diuretics (95.9%), beta-blockers (82.5%), angiotensin-co

47 w ascites and peripheral edema, treated with diuretics, a low-salt diet, and fluid restriction.

48 he compounds currently in clinical trials as diuretics, a series of 1,4-substituted 8-cyclohexyl and

49 for a particular drug (PPIs, NSAIDs, SSRIs, diuretics, ACE inhibitors) in the 6 months prior to the

50 monly used antihypertensive agents including diuretics, ACE inhibitors, and ARBs.

51 Thiazide diuretics, ACE-inhibitors or angiotensin receptor blocke

52 el antihypertensive therapy (mostly thiazide diuretics) added as needed to control blood pressure.

53 EI and ACEI+BB cohorts compared to that with diuretics alone were $444 and $33, respectively.

54 AHF therapies, such as diuretics, alter chloride homeostasis.

55 diuretic doses, and delays in the timing of diuretics among patients with acute decompensated heart

56 .35, and to have been treated optimally with diuretics and angiotensin-converting enzyme inhibitors u

57 nction, and are on background treatment with diuretics and angiotensin-converting enzyme inhibitors.

58 Diuretics and anticoagulants were underutilized in women

59 ally in part by overcoming the resistance to diuretics and atrial-natriuretic-peptide and inhibiting

60 Beneficiaries initiating diuretics and beneficiaries initiating digoxin were more

61 n separate classes, with lowest adherence to diuretics and beta-blockers and highest adherence to ang

62 Risks were similar for ACE inhibitors plus diuretics and beta-blockers plus diuretics.

63 nsin-converting enzyme inhibitors or between diuretics and beta-blockers.

64 d LVSD therapies (neurohormonal antagonists, diuretics and cardiac resynchronization in appropriate c

65 s to determine the relationship between loop diuretics and clinical outcomes in patients with HF.

66 ation of incontinence, medications including diuretics and estrogen, obstetric history, physical exam

67 ,864 subjects; of these, 5,320 received loop diuretics and had dose data recorded.

68 of BP response of thiazide and thiazide-like diuretics and help identify the patients better suited f

69 es most strongly support the use of thiazide diuretics and long-acting calcium channel blockers as fi

70 or antagonist, enhances the response to loop diuretics and may have a renal protective effect.

71 ss by exercise training, sodium retention by diuretics and monitoring devices, myocardial nitric oxid

72 ckers, calcium-channel blockers, or thiazide diuretics and the likelihood of a positive or negative r

73 sms and sites of action of loop and thiazide diuretics and the similarity of their chronic effects to

74 of clinically important drugs including loop diuretics and their disruption has been implicated in pa

75 nd may be responsible for both resistance to diuretics and to endogenous natriuretic peptides.

76 summarizes available data on the use of both diuretics and UF in ADHF patients and identifies challen

77 in 11 patients we withdrew beta-blockers and diuretics and used phenylephrine and albumin infusion to

78 Despite inpatient diuretics and vasodilators targeting decongestion, persi

79 lcohol consumption, hypertension, and use of diuretics and was inversely associated with physical act

80 hibitors, angiotensin-receptor blockers, and diuretics and/or beta blockers in the prevention of hear

81 uncontrolled hypertension (P=0.049), need of diuretics, and age <60 years (P=0.016) were associated w

82 mic beta blockers, calcium channel blockers, diuretics, and angiotensin receptor antagonists), smokin

83 et agents, warfarin, statins, beta-blockers, diuretics, and antiarrhythmic drugs.

84 h with the use of ARBs, ACEi, beta blockers, diuretics, and CCBs.

85 that was successfully treated with steroids, diuretics, and dose interruptions.

86 selection and doses of thiazide and similar diuretics, and the association of antihypertensive drug

87 A low eGFR, age <60 years, need of diuretics, and uncontrolled hypertension identify patien

88 uric, nonsteroidal anti-inflammatories, loop diuretics, angiotensin II receptor antagonists, and beta

89 y used antihypertensive medications included diuretics, angiotensin-converting enzyme inhibitors (ACE

90 At 1 year, use of added open-label atenolol, diuretics, angiotensin-converting enzyme inhibitors, and

91 Hypersensitivity to thiazide and loop diuretics, angiotensin-converting enzyme inhibitors, and

92 Routine therapy included use of digoxin, diuretics, angiotensin-converting enzyme inhibitors, and

93 -line drug classes thiazide or thiazide-like diuretics, angiotensin-converting enzyme inhibitors, ang

94 lure often progresses despite treatment with diuretics, angiotensin-converting enzyme inhibitors, bet

95 io to receive optimal pharmacologic therapy (diuretics, angiotensin-converting-enzyme inhibitors, bet

96 erapeutically important compounds, including diuretics, anticonvulsants and antidepressants, many of

97 commonly prescribed drugs (e.g. penicillins, diuretics, antivirals, methotrexate, and non-steroidal a

98 Thiazide diuretics are among the most commonly prescribed antihyp

99 Thiazide diuretics are among the most widely used treatments for

100 Loop diuretics are an essential component of therapy for pati

101 Thiazide-type diuretics are associated with an increased incidence of

102 Loop diuretics are commonly used to control congestive sympto

103 Diuretics are commonly used to treat hypertension and ex

104 Distal diuretics are considered less effective than loop diuret

105 l hypertension remains unknown, but thiazide diuretics are frequently recommended as first-line treat

106 Thiazide diuretics are frequently used in these patients for trea

107 To investigate whether distal diuretics are noninferior to dietary sodium restriction

108 Distal diuretics are noninferior to dietary sodium restriction

109 Loop diuretics are one of the cornerstones of treatments for

110 The initial ALLHAT conclusion, that thiazide diuretics are superior to angiotensin-converting enzyme

111 Diuretics are superior to calcium channel blockers and,

112 Intravenous loop diuretics are the mainstay of therapy for patients with

113 Low-dose diuretics are the most effective first-line treatment fo

114 Loop diuretics are used for congestion relief, and dose adapt

115 Diuretics are used in volume-expanded patients.

116 Osmotic diuretics are used successfully to alleviate acute tubul

117 Diuretics are used to decongest patients; however, morta

118 Thiazide diuretics are used to treat hypertension; however, compe

119 Thiazide diuretics are used worldwide as a first-choice drug for

120 e its cardinal manifestations for which loop diuretics are used.

121 ntly better than thiazides and thiazide-like diuretics as a first-line therapy for any outcome.

122 dence, and future trials should use low-dose diuretics as the standard for clinically useful comparis

123 erenone would lead clinicians to reduce loop diuretics, as a consequence of the improvement in patien

124 s were found between groups for use of other diuretics, aspirin, antidepressants, antiepileptics, ant

125 Evaluation of Survival Trial) receiving loop diuretics at baseline were analyzed (N = 2,456).

126 6 patients, 5,568 (70%) were prescribed loop diuretics at discharge.

127 : (1) observational: patients receiving loop diuretics at the Yale Transitional Care Center (N=162) a

128 ith HF (n=128) receiving treatment with loop diuretics at the Yale Transitional Care Center.

129 ALLHAT conclusion that thiazide and similar diuretics (at evidence-based doses) are the preferred fi

130 -1.66; 95% CI, -2.57 to -0.75; P < 0.001) or diuretics (beta = -1.38; 95% CI, -2.59 to -0.17; P < 0.0

131 -2.44; 95% CI, -3.99 to -0.89; P = 0.002) or diuretics (beta = -2.76; 95% CI, -4.76 to -0.76; P = 0.0

132 ontrast media, antiinflamatory, cytostatics, diuretics, beta blockers, anesthetics, analgesics, antie

133 total energy intake, body mass index, use of diuretics, beta-blockers, allopurinol, and uricosuric ag

134 Overall, the use of thiazide diuretics, beta-blockers, angiotensin-converting enzyme

135 iabetes, hypertension medications, including diuretics, blood lead levels, and hyperlipidemia, the od

136 cs) to identify novel biomarkers of thiazide diuretics BP response.

137 VASP as a potential determinant of thiazide diuretics BP response.

138 ce NKCC2 is the molecular target of the loop diuretics bumetanide and furosemide, we asked about thei

139 lkalosis impairs the natriuretic response to diuretics, but the underlying mechanisms are unclear.

140 potassium after the initiation of digoxin or diuretics by Medicare beneficiaries.

141 I receptor blockers, beta-blockers, thiazide diuretics, calcium channel blockers, and metformin.

142 c therapy using any of several thiazide-type diuretics can more than double daily urine sodium excret

143 better suited for thiazide and thiazide-like diuretics compared to beta-blockers for improved BP mana

144 onger median time to the second dose of loop diuretics compared with long call patients (17.9 hours v

145 Conversely, there was lower adherence to diuretics compared with the other drug classes.

146 tense neurohumoral antagonism, limitation of diuretics, correction of hypokalemia, exercise, and diet

147 and right ventricular stroke volume, whereas diuretics decreased right ventricular preload and right

148 Rodents chronically administered loop diuretics develop DR due to compensatory distal tubular

149 Diuretics, developed more than four decades ago, are use

150 decreased albuminuria significantly, whereas diuretics did significantly reduce urinary angiotensinog

151 angiotensin-converting enzyme inhibitor and diuretics, digoxin had no effect on natural history end

152 nce of comorbidities, and were more often on diuretics, digoxin, and angiotensin converting enzyme in

153 herapy for congestive heart failure, such as diuretics, digoxin, angiotensin-converting enzyme inhibi

154 e formation of mineralized nodules, but loop diuretics do not.

155 uretic resistance, ultrafiltration before IV diuretics effectively and safely decreases length of sta

156 Using propensity scores for receipt of loop diuretics estimated for each of the 7,936 patients, a ma

157 ocardial Infarction), many patients required diuretics for congestion relief.

158 pensation (HF hospitalization or intravenous diuretics for HF without hospitalization), and with elev

159 DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease

160 ould represent a target for new and improved diuretics for the treatment of hypertension and heart fa

161 otassium channel, ROMK, will represent novel diuretics for the treatment of hypertension.

162 ounder of epidemiology studies is the use of diuretics for treating hypertension.

163 When combined with diuretics, fully additive BP reduction is seen.

164 d in the ultrafiltration group and 11 in the diuretics group.

165 o received a discharge prescription for loop diuretics had significantly better 30-day clinical outco

166 decompensated heart failure (ADHF), and loop diuretics have historically been the cornerstone of trea

167 that men using NSAIDs, statins, and thiazide diuretics have reduced PSA levels by clinically relevant

168 Loop diuretics have well-described toxicities, and loss of re

169 es associated with the use of high-dose loop diuretics (HDLD).

170 .57; 95% confidence interval, 1.38 to 1.79), diuretics (HR, 1.95; 95% confidence interval, 1.73 to 2.

171 On univariable analysis, only diuretics, hsCRP, GZ, and core scar were associated with

172 ely with standard medical therapy, including diuretics, if they develop symptoms suggestive of heart

173 Diuretics improve symptoms but should be used in additio

174 an in addition to standard therapy including diuretics improved many, though not all, heart failure s

175 7 +/- 3.5 h of hospitalization and before IV diuretics in 20 heart failure patients with volume overl

176 ded transient dasatinib interruption in 83%, diuretics in 71%, pulse steroids in 27%, and thoracentes

177 tics are considered less effective than loop diuretics in CKD.

178 trial (SGLT2 Inhibition in Combination With Diuretics in Heart Failure) was a randomized, double-bli

179 The demonstrated efficacy of loop diuretics in managing congestion is balanced by the reco

180 our study demonstrate increased use of loop diuretics in patients with BP before the development of

181 e if ultrafiltration before intravenous (IV) diuretics in patients with decompensated heart failure a

182 tration may be an alternative to intravenous diuretics in patients with decompensated HF and volume o

183 luating the combination of loop and thiazide diuretics in patients with heart failure in order to des

184 llowed by CCB and placebo, beta blockers and diuretics in rank order.

185 late osmotic stability are disrupted by loop diuretics in rats.

186 acokinetics is essential for skillful use of diuretics in the management of heart failure in both the

187 The efficacy of diuretics in the management of rosiglitazone (RSG)-induc

188 are not understood, including the action of diuretics in the treatment of ascites and the ability of

189 ous antiarrhythmic drug use, previous use of diuretics, increased left atrial diameter, increased lef

190 and NF-kappaB activation produced by osmotic diuretics, indicating a role of adenosine metabolites in

191 al diuretic, or any intravenous therapy with diuretics, inotropes, or other vasoactive agents.

192 ons of the current therapeutic regimens with diuretics, intravenous vasodilators (ie, nitroglycerin,

193 el mechanisms of nephroprotection by osmotic diuretics, involving both activation and induction of th

194 Potassium depletion by thiazide diuretics is associated with a rise in blood glucose.

195 hen administration of moderate doses of loop diuretics is not sufficient, patients can be treated wit

196 clinical trial evidence to guide the use of diuretics is sparse.

197 weight loss needs clarification, the role of diuretics is uncertain, and which surgical intervention

198 oconcentration received higher doses of loop diuretics, lost more weight/fluid, and had greater reduc

199 that inexpensive and well-tolerated thiazide diuretics may be especially effective in preventing the

200 in cells expressing NCC, indicating thiazide diuretics may be particularly effective for lowering BP

201 Thus, despite concerns that some diuretics may cause harm by neurohormonal activation, th

202 vious concerns about the safety of high-dose diuretics may not be valid.

203 beta-receptor blockers, digoxin and thiazide diuretics may worsen sexual dysfunction owing to medicat

204 s for HFpEF but evidence supports the use of diuretics, mineralocorticoid antagonists and lifestyle i

205 brillation; and moderate dose of intravenous diuretics (n = 200).

206 = 437), calcium-channel blockers (n = 223), diuretics (n = 226), and combinations (n = 1,442), beta-

207 Patients treated with diuretics (n=4) displayed higher abundance of full-lengt

208 in a control cohort without HF not receiving diuretics (n=52; 16.6%+/-9.2%; P=0.82).

209 Thiazide diuretics, niacin, and beta-adrenergic blockers impair g

210 rs, beta-blockers, calcium channel blockers, diuretics, nitrates, statins, insulin, biguanides, sulfo

211 1.17-2.62), and IV fluids, electrolytes, or diuretics (odds ratio, 1.73; 95% CI, 1.21-2.48) at trans

212 nd ACEI+BB strictly dominated treatment with diuretics only (cost-saving).

213 rate (eGFR) less than 50 mL/min, and taking diuretics or cyclosporine were associated with hyperuric

214 In Medicare beneficiaries initiating diuretics or digoxin, this study examined disparities in

215 bate cardiovascular problems from overuse of diuretics or inotropes because of the unusual loading co

216 , are usually treated with potassium-sparing diuretics or nonsteroidal anti-inflammatory drugs and or

217 ion of participants who were taking thiazide diuretics or those with diabetes.

218 te MI was present among nonusers of alcohol, diuretics, or aspirin and among those who did not have m

219 Loop diuretics other than furosemide were converted to furose

220 iles also favoured thiazide or thiazide-like diuretics over angiotensin-converting enzyme inhibitors.

221 ic patients were more likely to be receiving diuretics (p < 0.0001) and have a lower mean corpuscular

222 t loss (p < 0.001), later transition to oral diuretics (p = 0.03), and shorter length of stay (p < 0.

223 with truly resistant hypertension, thiazide diuretics, particularly chlorthalidone, should be consid

224 when prescribing long-term beta-blockers and diuretics, particularly in patients at high risk of deve

225 correcting for relevant variables (including diuretics, pH, potassium levels and renal sodium excreti

226 events of coronary heart disease or stroke, diuretics plus ACE inhibitors or calcium channel blocker

227 calcium channel blockers did not differ from diuretics plus beta-blockers.

228 glycerides at baseline, high blood pressure, diuretics, pre-enrollment weight change, dieting, total

229 Hospitalized older patients not taking diuretics prior to hospitalization for HF decompensation

230 Diuretics produced a greater reduction in 24-hour systol

231 it from the use of chronic diuretic therapy, diuretics rapidly improve symptoms associated with volum

232 Diuretics reduce the rate of action potential fall in th

233 eater weight and fluid loss than intravenous diuretics, reduces 90-day resource utilization for HF, a

234 0.7 [95% confidence interval, 0.57-0.82] for diuretics; relative risk, 0.8 [95% confidence interval,

235 inition that excluded the intensification of diuretics resulted in a lower event rate but a stronger

236 uresis, particularly when combined with loop diuretics, resulting in an improvement in blood volume.

237 eta-blockers, calcium channel blockers, loop diuretics, selective serotonin reuptake inhibitors, stat

238 pressin receptor antagonists, urea, and loop diuretics serve this purpose, but received different rec

239 tors' original conclusion that thiazide-type diuretics should remain the preferred first-step drug cl

240 classes; however, thiazide or thiazide-like diuretics showed better primary effectiveness than angio

241 The combination of statins and thiazide diuretics showed the greatest reduction in PSA levels: 3

242 The diuretics spironolactone and trichlormethiazide, but not

243 ymptomatic management may include the use of diuretics, statins, infection prophylaxis and anticoagul

244 unds (mixture of anabolics, beta-2 agonists, diuretics, stimulants, narcotics, and beta-blockers) spi

245 the K-Cl cotransporter is dominated by loop diuretics such as furosemide and bumetanide, molecules u

246 Traditional diuretics such as furosemide induce substantial neurohor

247 h the exception of thiazide or thiazide-like diuretics superiority to angiotensin-converting enzyme i

248 n developing new classes of antihypertensive diuretics targeting ROMK.

249 was confirmed by the natriuretic response to diuretics targeting the thick ascending limb, the distal

250 Thiazide diuretics (TD) are commonly prescribed anti-hypertensive

251 2 inhibitors are proximal tubule and osmotic diuretics that reduce volume retention and blood pressur

252 Treatment with loop diuretics, the current cornerstone of decongestive treat

253 In contrast to diuretics, the vasopressin antagonist tolvaptan may incr

254 ts otherwise resistant to high doses of loop diuretics, this strategy has not been subjected to large

255 nitroglycerin, or nesiritide in addition to diuretics to achieve hemodynamic and symptomatic improve

256 e enhancing drugs in sports as athletes take diuretics to dilute the concentration of drugs in their

257 uggest that administration of high-dose loop diuretics to patients with HF yields meaningful increase

258 Treatment strategies include the use of diuretics to relieve symptoms and application of an expa

259 in converting enzyme (ACE) inhibitor or loop diuretics to those 75 years or older without assessment

260 Thiazide diuretics treat the disease, fostering the view that hyp

261 UT-B inhibitors represent a new class of diuretics, "urearetics," which are predicted to increase

262 od pressure less than 140/90 mm Hg; thiazide diuretics used in multidrug hypertensive regimen; athero

263 ass regimen of calcium channel blockers plus diuretics was associated with a higher risk of CVD morta

264 Monotherapy with calcium channel blockers vs diuretics was associated with greater risk of CVD death

265 Only the intake of diuretics was associated with substantially increased NT

266 roups, respectively (HR when the use of loop diuretics was compared with nonuse: 0.73; 95% CI: 0.57 t

267 Monotherapy with diuretics was equal or superior to other monotherapy in

268 reduction in office SBP produced by the two diuretics was identical, further strengthening the case

269 enal function (p = 0.01), whereas total dose diuretics was lower in patients with hemoconcentration (

270 ding intravenous treatment with inotropes or diuretics was the most common adverse event (in 20 [2%]

271 or other antihypertensive therapy (excluding diuretics) was administered at year 1.

272 n, adiposity, weight gain, hypertension, and diuretics were all found to be independent risk factors

273 more antihypertensive medications, ACEI, and diuretics were associated with a loss of structural mark

274 Compared with beta-blockers, low-dose diuretics were associated with a reduced risk of cardiov

275 Thiazide and loop diuretics were associated with higher risk of incident g

276 Thiazide and loop diuretics were associated with increased gout risk, an a

277 Compared with alpha-blockers, low-dose diuretics were associated with reduced risks of CHF (RR,

278 Compared with ACE inhibitors, low-dose diuretics were associated with reduced risks of CHF (RR,

279 nd scheduled treatment with intravenous loop diuretics were included.

280 itted to the ED and who received intravenous diuretics were included.

281 Beneficiaries initiating diuretics were less likely to have testing if they were

282 calcium channel blockers (CCB), insulin, and diuretics were significantly higher in the periodontitis

283 , calcium channel blockers were inferior and diuretics were superior to other drug classes.

284 For all outcomes, low-dose diuretics were superior to placebo: coronary heart disea

285 Loop or thiazide diuretics were used in all 14 patients, and angiotensin-

286 Loop diuretics were used significantly more frequently by the

287 of the kidney and is the target of thiazide diuretics, which are commonly prescribed to treat hypert

288 Disease features are reversed by thiazide diuretics, which inhibit the Na-Cl cotransporter in the

289 ulating blood decreases with the use of loop diuretics, which might result in less immediate transloc

290 rs may complement the action of conventional diuretics, which target sodium transport.

291 ept for NSAIDs, ACE inhibitors, and thiazide diuretics, which were more prevalent in black patients.

292 between the two groups with the exception of diuretics, which were used more often in the DWGF group.

293 re likely to be treated with higher doses of diuretics, while higher filling pressures, N-terminal pr

294 Beneficiaries initiating diuretics with laboratory values were more likely to hav

295 bitors are first in their class salt-sparing diuretics with potential clinical indications in volume-

296 lockers, calcium-channel blockers [CCBs], or diuretics) with follow-up of at least 1 year.

297 n reuptake inhibitors, statins, and thiazide diuretics), with evaluation of how often drugs were wide

298 r more effective fluid removal compared with diuretics, with improved quality of life and reduced reh

299 ive management includes salt restriction and diuretics, with thoracentesis and transjugular intrahepa

300 study treatment in the following subgroups: diuretics (yes/no), digitalis glycoside (yes/no), minera